Bispecifics for Relapsed and Refractory Multiple Myeloma Patients

Managing Responses to Bispecific Antibodies

Is there a test that can predict which patients will respond to bispecific antibodies? And is response different based on which protein is targeted? Myeloma expert Hans Lee, MD, associate professor and director at The University of Texas MD Anderson Cancer Center, discusses these questions and more in part four of our five-part series on bispecifics.

© 2024 HealthCentral LLC. All rights reserved.

Bispecifics for Relapsed and Refractory Multiple Myeloma Patients